Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)
Despite proven survival benefits, avelumab uptake in real-world practice is limited by barriers like access, reimbursement, and awareness. These findings align with JAVELIN 100 and underscore the need for further real-world studies to address treatment disparities.
Authors
- M. Arruti Ibarbia
- Mireia Peláez (ORCID: https://orcid.org/0000-0001-8022-4925)
- Laura Basterretxea (ORCID: https://orcid.org/0000-0001-8450-713X)
- Marta Sotelo
- Verónica Calderero Aragón
- M. Martínez Kareaga (ORCID: https://orcid.org/0000-0002-2599-5791)
- Ricardo Sánchez-Escribano (ORCID: https://orcid.org/0000-0002-5953-2867)
- Ricardo Fernández (ORCID: https://orcid.org/0009-0001-2331-135X)
- E. Pujol Obis
- Cristina Mazas Pérez-Oleaga (ORCID: https://orcid.org/0000-0001-7009-1567)
- Núria Laínez
- Carmen Santander
- Carlos Álvarez Fernández (ORCID: https://orcid.org/0000-0002-9070-556X)
- Irene Gil Arnáiz
- Ignacio Durán
- Estrella Varga
- Inmaculada Rodríguez Ledesma
- Pablo Piedra
- J.A. Verdún Aguilar
Institutions
- Hospital Txagorritxu (ES)
- Hospital Universitario Araba (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario de Burgos (ES)
- Hospital de Galdakao (ES)
- Hospital Universitario Reina Sofía (ES)
- Universidad Europea del Atlántico (ES)
- Hospital Universitario Central de Asturias (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Hospital de Cruces (ES)
- Donostiako Unibertsitate Ospitalea (ES)
- Hospital General San Jorge (ES)
- Hospital Clínico Universitario de Valladolid (ES)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1007/s12094-025-03950-w
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Astellas Pharma